|
 Paul F. Duffy, Managing Principal
Mr. Duffy
brings Black Mountain Consulting Group extensive experience at both
big pharma and start-up organizations. He acquired more than
30 years of big pharma experience at Novartis Pharmaceuticals
(formerly Sandoz Pharmaceuticals), having held sales and marketing
positions of increasing responsibility from 1972 to 2003, when he
served as U.S. National Sales Director-Neuroscience. Mr. Duffy then
left Novartis to co-found CNS start-up Alamo Pharmaceuticals, where
he served as Executive Vice President. At Alamo, he created a fully
integrated commercial pharmaceutical company to market Fazaclo, a
patented reformulation of Novartis' anti-psychotic drug, Clozaril.
Duffy left Alamo in July 2006, after completing its sale to Avanir
Pharmaceuticals.
He then
became founding CEO of Validus Pharmaceuticals, creating an entirely
new type of private-equity backed pharmaceutical company. Most
recently, Duffy served as President—US Commercial Operations for the
UK-based multinational, Amarin Pharmaceuticals.
|
|
|
 Josh Weinstein,
Principal
Josh
Weinstein has been formulating creative pharmaceutical marketing
solutions since 1968. His particular specialty is translating
complex science into marketing claims that are easy to understand
and visualize. Mr. Weinstein’s marketing
communications expertise was honed in a career extending from
physician and hospital sales, product management, new product
development and launches to managing the nation’s most successful
advocacy and public education campaign.
For the past
12 years Weinstein has served as President of jwEinstein Strategic
Messaging, Inc., a full service advertising, PR and advocacy
development company that specializes in helping start-ups and young
pharma and device companies to promote, license and launch new
technologies and products, as well as re-launch more mature
products. Mr. Weinstein’s career began at Sandoz Pharmaceuticals
(now Novartis) where he served in numerous field and marketing
capacities culminating in the launch campaigns for Tavist and
Visken. Weinstein then joined Schering-Plough where he became
Director of Marketing and launched Normodyne and Intron-A
(alfa-interferon) which is now a multi-billion dollar product. After
moving to Schering International, to manage a developing
cardiovascular pipeline, he was recruited by Squibb where, as Vice
President of Marketing, he managed their entire US Product line as
well the development of Pravachol (one of the nation’s first
‘statins’).
With the
advent of biotechnology companies, Weinstein became an independent
consultant to numerous start-ups as well as larger firms in need of
pharma expertise. As a result, he was recruited to run the New York
Healthcare operation of the prestigious public relations firm, Hill
& Knowlton, and later to join PR giant, Burson-Marstellar,
sharing time between their
Washington,
DC and
New York
healthcare operations. Subsequently,
Mr. Weinstein was recruited by McCann-Erickson’s Torre-Lazur and
Weber divisions to start-up a new healthcare PR firm, and, later
serve as founding President for the Torre-Lazur-McCann
Global Advocacy Group.
 Michael A. Leone,
Principal
Mike
Leone is recognized as an accomplished pharmaceutical executive with
broad therapeutic expertise.
His over 25 years of experience and leadership includes
positions of increasing senior level responsibility at Bristol-Myers
Squibb, First Horizon Pharmaceuticals, Eyetech Pharmaceuticals and
Takeda Pharmaceuticals North America. Mike is currently President of
Strategic HealthCare Resources, LLC, and is consulting for a number
of venture capital, pharmaceutical, biotech and device companies. He
has helped companies create sales force deployment models, developed
compensation models, served as a direct customer liaison with state
Medicaid and federal government customers on formulary and
pharmacoeconomic issues, consulted on clinical trial focus areas,
conducted focused leadership training programs, and counseled a
growing sales organization on how to enhance the structure of its
organization and improve the capabilities of its leaders.
Having
spent the majority of his career at Bristol-Myers Squibb, Mr. Leone
held numerous positions of increasing responsibility. These positions included
National Director, Federal & Institutional Sales, a position in
which he rebuilt the Hospital Sales Team and strengthened BMS’ role
and commitment to VA and military customers. In that role, Mike
spearheaded the institutional launches of Maxipime and Plavix. Mike’s National Accounts
experience, and focused, field-based hospital sales leadership
expertise have made him an especially valuable asset to Specialty
Pharma clients.
|
|
